Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Alcon Research, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Alcon Research, LLC

Regulatory records
14
Linked recall entries
13
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 14 FDA records to the applicant name Alcon Research, LLC. It includes 2 original PMA approvals. 2 entries are PMA supplements. 10 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 2, 2024 to Sep 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LPO appears in 12 of the 14 linked filings. The collection spans 2 FDA product codes and 3 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220030, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 4 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 20511 Lake Forest Dr., Lake Forest, CA, 92630. Recorded on P230012/S012, decision dated Sep 30, 2026.

Changes described in PMA records

P230012/S012: UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA recorded a 30-Day Notice decision (OK30) dated 2026-09-30 for P230012/S012, a supplement to the UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The recorded scope covers three manufacturing changes: an alternate supplier for UNIFEYE screen and pad printing operations, an alternate third-party supplier of ink and additive for printed components, and an alternate third-party supplier for machining and passivating the Valve Seat component.

This action concerns the manufacturing supply chain for the delivery system rather than a new approval of the gas or the complete system. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. No supporting documents were included in the source record, so the review basis, any testing performed and whether labeling changed remain unknown.

The OK30 code is reported as recorded; its precise administrative meaning is not defined in the source data and is not interpreted here.

FDA approval-order wording

Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.

Sep 30, 2026 · 30-Day Notice

P220030/S012: UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA recorded an OK30 decision dated 2026-09-30 for P220030/S012, a 30-Day Notice supplement to the approved application for UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The action covers the recorded manufacturing changes only; it is not a new approval of the gas or the delivery system as a whole.

The recorded changes are three: an alternate supplier for UNIFEYE screen and pad printing operations; an alternate third-party supplier of ink and additive for printed components; and an alternate third-party supplier for machining and passivating the Valve Seat component. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. The source record includes no documents, so the review basis and any supplier qualification details remain unknown.

FDA approval-order wording

Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.

Sep 30, 2026 · 30-Day Notice

P170034/S018: Hydrus Microstent

FDA’s recorded scope: approval for an alternative raw material supplier for Nitinol (NiTi) Tubing

Jun 4, 2026 · 30-Day Notice

P220030/S011: UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA’s recorded scope: addition of a UNIFEYE nose piece bonding fixture used on the UNIFEYE check valve subassembly during the bonding and curing processes, changing from a manual to an automated torque test fixture to verify the bonding; and updating to the torque test method used during the UNIFEYE final assembly process for torque testing of the UNIFEYE check valve and mixture stop subassemblies.

May 28, 2026 · 30-Day Notice

P230012/S011: UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery System

FDA’s recorded scope: addition of a UNIFEYE nose piece bonding fixture used on the UNIFEYE check valve subassembly during the bonding and curing processes, changing from a manual to an automated torque test fixture to verify the bonding; and updating to the torque test method used during the UNIFEYE final assembly process for torque testing of the UNIFEYE check valve and mixture stop subassemblies.

May 28, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 13 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class I, 12 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Alcon Research, LLCClass IDec 31, 2025FDA
CONSTELLATION ULTRAVIT 10K and CONSTELLATION HYPERVIT 20K, Description/REF: 25+ TOTALPLUS CP PAK 20K CPM BWV .9 IU/ 8065000093; 25+ TOTALPLUS CP PAK 20K CPM BV .9 IU/ 8065000095; 27+ TOTALPLUS CP PAK 20K CPM BV .9 IU/ 8065000096; 23GA BEVEL ULTRAVIT 10,000 CPM/ 8065752413; 25+ BEVEL ULTRAVIT 10,000 CPM/ 8065752415; 27+ BEVEL ULTRAVIT 10,000 CPM/ 8065752417; TOTAL PLUS,23G,10K VALVE STD/ 8065752435; TOTAL PLUS,23GA,10K VALVE WD/ 8065752436; TOTAL PLUS,25+,10K VALVE STD/ 8065752437; TOTAL PLUS,25+,10K VALVE WD/ 8065752438; TOTAL PLUS,27+,10K VALVE STD/ 8065752439; 23G CMB PAK 10K CPM,V,STD 0.9/ 8065752448; 23G CMB PAK 10K CPM,V,WA 0.9/ 8065752449; 25+ CMB PAK 10K CPM,V,STD 0.9/ 8065752450; 25+ CMB PAK 10K CPM,V,WA 0.9/ 8065752451; 27+ CMB PAK 10K CPM,V,STD 0.9/ 8065752452; 25+TTLPL VPK 20000CPM BEV VAL/ 8065753106; 27+TTLPL VPK 20000CPM BEV VL/ 8065753109; HYPERVIT 25+BEV 20000 CPM/ 8065830026; HYPERVIT 27+BEV 20000 CPM/ 8065830027; 25+ TTL PLUS VPAK 20000CPM BWV/ 8065830077; 25G VIT 25G OPTICARE EYE HLTH CTR/ 10924-15; VITRECTOMY 25G NORTHSIDE HOSP/ 11220-25; VITRECTOMY 25G NORTHSIDE HOSP/ 11220-27; 23G CONSTELLATION NORTHERN MICH SPPLY AL/ 12568-09; AUS-25GA VIT RET BRISBANE WATERS/ 12641-13; AUS-25GA VIT RET BRISBANE WATERS/ 12641-14; AUS-23GA 10K COMBINED VR PAK NEW CHILDRE/ 12852-16; 23G VIT CONSTELLATION LOMA LINDA COMM HO/ 13501-08; 25+G 20K VIT CONSTELLATION LOMA LINDA CO/ 13502-10; 23G VIT CONSTELLATION VALVED BAYSTATE ME/ 13591-13; 25G CONSTELLATION VALVED BAYSTATE MEDICA/ 13592-15; VITRECTOMY 25G V A HOSPITAL/ 14129-10; J-COMB PAK - 25G 20K CVS NAKAGAMI HOSPIT/ 14283-12; CDN-CVS VIT 25G VE 10K TIMMINS DH/ 14501-09; CDN-CVS VIT 25G+ VE 10K CIUSSS MCQ/ 14512-09; CDN-CVS VIT 25G+ VE 10K CIUSSS MCQ/ 14512-10; CDN-CVS VIT 23G 10K WA SASKATOON HR/ 14532-06; CDN-CVS VIT 23G 10K WA SASKATOON HR/ 14532-07; CDN-CVS VIT 10K 25G+ HSC, ST JOHN'S/ 14540-08; CDN-CVS COMBO 23G VE 10K HD KINGSTON/ 14541-16; CDN-CVS VIT 25G+ 20K BV JEWISH GH/ 14597-07; CDN-CVS VIT 23G 10K ROCKYVIEW HOSPITAL/ 14603-15; CDN-CVS COMBO 25G VE 10K TIMMINS DH/ 14669-10; CDN-CVS COMBO 25G VE 10K TIMMINS DH/ 14669-11; CDN-CVS VIT 23G VE ROYAL ALEXANDRA HOSP/ 14671-09; CDN-CVS VIT 25G+ 10K ROCKYVIEW HOSPITAL/ 14672-11; CDN-CVS VIT 25G+ BWV 20K CUSM/MUHC/ 14873-06; CDN-CVS VIT 25G+ BWV 20K CUSM-MUHC/ 14873-07; CDN-VIT 23G VE 10K ST MICHAEL'S HOSP/ 14955-08; CDN-VIT 23G VE 10K ST MICHAELS HOSP/ 14955-09; CDN-CVS 25G+ VIT VE 10K ST MICHAEL'S/ 14956-07; CDN-CVS 25G+ VIT VE 10K ST MICHAELS/ 14956-08; CDN-CVS VIT 25G+ 10K WESTERN MH/ 15006-06; CDN-CVS VIT 25G+ 20K WA WESTERN MH/ 15006-07; CDN-CVS COMBO 23G 10K ROCKYVIEW HOSPITAL/ 15108-09; CDN-CVS CMB 25G+ V 10K OAKVILLE-TRAFALGA/ 15167-08; 25G PLUS VITRECTOMY PEACE HEALTH ST JOSE/ 15223-13; CDN-VIT 23G 10K GRM741746 CUO-HSS/ 15294-14; CDN-COMBO 23G 10K GRM741759 CUO-HSS/ 15295-12; CDN-CVS VIT 25G+ VE 10K MISERICORDIA HC/ 15318-05; CDN-CVS VIT 25G+ VE 10K MISERICORDIA HC/ 15318-06; CDN-CVS VIT 25G+ VE 10K MISERICORDIA HC/ 15318-07; CDN-CVS COMBO 23G V 10K ST MICHAEL'S HSP/ 15324-07; CDN-COMBO 25G 20K GRM743287 CUO-HSS/ 15421-13; CDN-COMBO 25G 20K GRM743287 CUO-HSS/ 15421-14; CDN-UHN 23G COMBO VE 10K TORONTO WESTERN/ 15455-08; CDN-UHN 23G COMBO VE 10K TORONTO WESTERN/ 15455-09; CDN-UHN 23G COMBO VE 10K TORONTO WESTERN/ 15455-10; CDN-UHN 23G VIT VE 10K TORONTO WESTERN/ 15456-04; CDN-UHN 23G VIT VE 10K TORONTO WESTERN/ 15456-05; CDN-UHN 23G VIT VE 10K TORONTO WESTERN/ 15456-06; CDN-CVS 23G COMBO VE 10K SUNNYBROOK GH/ 15464-05; CDN-CVS 23G VIT VE 10K SUNNYBROOK GH/ 15465-05; 23G VIT PACK CALLAHAN EYE FOUNDATION HOS/ 15491-05; 23G VIT PACK CALLAHAN EYE FOUNDATION HOS/ 15491-06; 27G VIT PACK CALLAHAN EYE FOUNDATION HOS/ 15492-02; 27G VIT PACK CALLAHAN EYE FOUNDATION HOS/ 15492-03; 25G+ VIT PACK CALLAHAN EYE FOUNDATION HO/ 15493-05; 25G+ VIT PACK CALLAHAN EYE FOUNDATION HO/ 15493-06; CDN-CVS VIT 25G+ 10K PASQUA HOSPITAL/ 15525-04; CDN-CVS COMBO 23G VE 10K KENSINGTON EI/ 15552-05; CDN-CVS 23G VIT VE 10K KENSINGTON EYE IN/ 1Z-0581-2026
Alcon Research, LLCClass IIDec 3, 2025FDA
Alcon Research, LLCClass IINov 5, 2025FDA
Alcon Research, LLCClass IINov 5, 2025FDA
Alcon Research, LLCClass IINov 5, 2025FDA
Alcon Research, LLCClass IINov 5, 2025FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Search the firm’s recall records
Source information

Source updated Nov 11, 2026. Retrieved Nov 20, 2026.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Research, LLCPMA supplementSep 30, 2026FDA
Alcon Research, LLCPMA supplementSep 30, 2026FDA
Hydrus MicrostentP170034/S018
Alcon Research, LLCPMA supplementJun 4, 2026FDA
Alcon Research, LLCPMA supplementMay 28, 2026FDA
Alcon Research, LLCPMA supplementMay 28, 2026FDA
Hydrus MicrostentP170034/S017
Alcon Research, LLCPMA supplementApr 23, 2026FDA
Alcon Research, LLCPMA supplementFeb 17, 2026FDA
Alcon Research, LLCPMA supplementFeb 17, 2026FDA
Alcon Research, LLCPMA supplementFeb 10, 2026FDA
Alcon Research, LLCPMA supplementFeb 10, 2026FDA
Alcon Research, LLCPMA supplementJan 8, 2026FDA
Alcon Research, LLCPMA supplementJan 8, 2026FDA
Alcon Research, LLCPMA approvalAug 26, 2024FDA
Alcon Research, LLCPMA approvalJul 2, 2024FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.